Latest News and Press Releases

BOSTON, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...

BOSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...

BOSTON, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company’s partner in China, Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), received...

BOSTON, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...

BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that Evan Loh, chief executive officer, will present at the 2021 Jefferies London Healthcare...

-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $19.4 Million from the Core Commercial Business alone, a 30% Increase over Prior Quarter -- BARDA Contract Expanded to Include sNDA Anthrax...

BOSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Monday, Nov. 8, 2021 at...

BOSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...

BOSTON, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the first patient has been enrolled in the company’s Phase 2b study evaluating the safety...

BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...